Tirzepatide (weekly injection)

🧮 Dose calculator

Type 2 diabetes mellitus · Regimen source: FDA Mounjaro · 2.1

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Mounjaro · 8.1

  “Risk Summary Available data with MOUNJARO use in pregnant women are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Mounjaro · 8.2

  “Risk Summary In a single-dose clinical lactation study, the concentration of tirzepatide in breast milk was found to be either undetectable or low compared to the maternal administered dose ( see Data ).”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Mounjaro · 8.4

  “The safety and effectiveness of MOUNJARO as an adjunct to diet and exercise to improve glycemic control in pediatric patients 10 years of age and older with type 2 diabetes mellitus have been established.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Mounjaro · 8.5

  “No overall differences in safety or effectiveness of MOUNJARO have been observed between patients 65 years of age and older and younger adult patients.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Mounjaro · 8.3

  “Contraception Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying.”